Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Adding amivantamab to chemotherapy improves overall survival in patients with advanced NSCLC harboring EGFR exon 20 insertion mutations, according to updated phase 3 PAPILLION trial data presented at WCLC 2026. Patients on the combo lived a median of 34.3 months vs. 27.9 months on chemo alone. Researchers say the regimen should be considered a foundational first-line treatment for this mutation subtype.
Updated data from the phase 3 PAPILLION trial, presented at the 2026 World Conference on Lung Cancer, show that adding amivantamab to first-line chemotherapy meaningfully improves outcomes for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion (ex20ins) mutations — a subtype historically difficult to treat.
The trial enrolled 308 treatment-naïve patients randomized to receive either amivantamab plus chemotherapy or chemotherapy alone. After a median follow-up of nearly 49 months, the combination arm demonstrated improvements not just in overall survival, but also in progression-free survival 2 (PFS2) and patient-reported outcomes. A crossover-adjusted analysis further strengthened the survival benefit of the combination.
By the Numbers:
Why it matters: EGFR ex20ins mutations have long lacked effective targeted options. These results cement amivantamab plus chemotherapy as a strong first-line standard for this patient population, offering clinicians a regimen with durable, broad-spectrum benefit.
